T0901317

Research use only, not for human use.

A potent, high affinity LXR agonist (EC50=50 nM, Kd are 7 and 22 nM for LXR-α and LXR-β respectively).

A potent, high affinity LXR agonist (EC50=50 nM, Kd are 7 and 22 nM for LXR-α and LXR-β respectively); upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and HDL metabolism; decreases amyloid-β production in primary neurons in vitro; displays an EC50 of ~ 5 μM for activation of FXRs.Alzheimer's Disease Discontinued.

Cell Proliferation Assay Cell Line:A2780, CaOV3 and SKOV3 ovarian cancer cell lines Concentration:5, 10, 20, 40 or 50 μMIncubation Time:72 hours Result:Inhibited cellular proliferation in all cell lines in a dose-dependent and time-dependent manner.Cell Cycle AnalysisCell Line:A2780, CaOV3 and SKOV3 cells Concentration:10 μM Incubation Time: 24, 48 or 72 hours Result:Decreased the percentage of cells in S phase and increased the percentage of cells in the G0/G1 phase.Apoptosis Analysis Cell Line:CaOV3 cells Concentration:10 to 40 μM Incubation Time:24 hours Result:Resulted in a significant increase of cells in early apoptosis.Western Blot Analysis Cell Line:CaOV3 cells Concentration:5 to 40 μM Incubation Time:48 hours Result:Resulted in an increase of p21 and p27 protein expression in a dose-dependent manner.

Animal Model:8- to 10-week-old LDL receptor null mice Dosage:10 mg/kg Administration:Orally; daily; for 12 weeks Result:Inhibited the progression of atherosclerosis.

T 0901317 | T-0901317

Nuclear Receptor/Transcription Factor

LXR

FXR|LXR

Neurological Disease

Alzheimer Disease

293754-55-9

481.3327

C17H12F9NO3S

>98% (HPLC)

DMSO: ≥ 27 mg/mL

OC(C(F)(F)F)(C(F)(F)F)C1=CC=C(N(CC(F)(F)F)S(C2=CC=CC=C2)(=O)=O)C=C1

Benzenesulfonamide, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-

(-20℃)

With Ice Pack

≥ 2 years